BACKGROUND & AIMS: Direct germline analysis could be used to screen high-risk patients for mutations in DNA mismatch repair genes associated with Lynch Syndrome. We examined the prevalence of mutations in MLH1, MSH2, and MSH6 in a population-based sample of patients with young-onset (age <50 years) colorectal cancer (CRC). METHODS: Young-onset CRC cases were randomly selected from 3 Colon Cancer Family Registry sites. DNA was extracted from peripheral blood leukocytes; MLH1, MSH2, and MSH6 were sequenced, and duplication and deletion analyses was performed for MLH1 and MSH2. Results were reported as deleterious or suspected deleterious, likely neutral, variant of uncertain significance, or no alteration detected. Germline data were compared to Amsterdam II criteria (ACII) and immunohistochemistry results in secondary analyses. RESULTS: Among 195 subjects, 11 had deleterious/suspected deleterious mutations (5.6%; 95% confidence interval [CI], 2.8%-9.9%), 12 had likely neutral alterations (6.2%; 95% CI, 3.2%-10.5%), 14 had variants of uncertain significance (7.2%; 95% CI, 4.0%-11.8%), 2 had a likely neutral alteration and a variant of uncertain significance (1.0%; 95% CI, 0.1%-3.7%), and 156 had no alteration detected (80.0%; 95% CI, 73.7%-85.4%). Sensitivity, specificity, and positive and negative predictive values for detecting deleterious/suspected deleterious mutations, based on ACII, were 36.4% (4/11), 96.7% (178/184), 40.0% (4/10), and 96.2% (178/185), respectively; based on immunohistochemistry these values were 85.7% (6/7), 91.9% (136/148), 33.3% (6/18), and 99.3% (136/137), respectively. CONCLUSIONS: In a population-based sample of young-onset CRC cases, germline mutations in MLH1, MSH, and/or MSH6 were more prevalent than reported for CRC patients overall. Because only about 5% of young-onset CRC cases had confirmed deleterious or suspected deleterious mutations, further comparative effectiveness research is needed to determine the most appropriate screening strategy for Lynch Syndrome in this high-risk group.
BACKGROUND & AIMS: Direct germline analysis could be used to screen high-risk patients for mutations in DNA mismatch repair genes associated with Lynch Syndrome. We examined the prevalence of mutations in MLH1, MSH2, and MSH6 in a population-based sample of patients with young-onset (age <50 years) colorectal cancer (CRC). METHODS: Young-onset CRC cases were randomly selected from 3 Colon Cancer Family Registry sites. DNA was extracted from peripheral blood leukocytes; MLH1, MSH2, and MSH6 were sequenced, and duplication and deletion analyses was performed for MLH1 and MSH2. Results were reported as deleterious or suspected deleterious, likely neutral, variant of uncertain significance, or no alteration detected. Germline data were compared to Amsterdam II criteria (ACII) and immunohistochemistry results in secondary analyses. RESULTS: Among 195 subjects, 11 had deleterious/suspected deleterious mutations (5.6%; 95% confidence interval [CI], 2.8%-9.9%), 12 had likely neutral alterations (6.2%; 95% CI, 3.2%-10.5%), 14 had variants of uncertain significance (7.2%; 95% CI, 4.0%-11.8%), 2 had a likely neutral alteration and a variant of uncertain significance (1.0%; 95% CI, 0.1%-3.7%), and 156 had no alteration detected (80.0%; 95% CI, 73.7%-85.4%). Sensitivity, specificity, and positive and negative predictive values for detecting deleterious/suspected deleterious mutations, based on ACII, were 36.4% (4/11), 96.7% (178/184), 40.0% (4/10), and 96.2% (178/185), respectively; based on immunohistochemistry these values were 85.7% (6/7), 91.9% (136/148), 33.3% (6/18), and 99.3% (136/137), respectively. CONCLUSIONS: In a population-based sample of young-onset CRC cases, germline mutations in MLH1, MSH, and/or MSH6 were more prevalent than reported for CRC patients overall. Because only about 5% of young-onset CRC cases had confirmed deleterious or suspected deleterious mutations, further comparative effectiveness research is needed to determine the most appropriate screening strategy for Lynch Syndrome in this high-risk group.
Authors: Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Mark Clendenning; Kaisa Sotamaa; Thomas Prior; Judith A Westman; Jenny Panescu; Dan Fix; Janet Lockman; Jennifer LaJeunesse; Ilene Comeras; Albert de la Chapelle Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: Andrea E de Jong; Yvonne M C Hendriks; Jan H Kleibeuker; Sybrand Y de Boer; Annemieke Cats; Gerrit Griffioen; Fokko M Nagengast; Frits G Nelis; Matti A Rookus; Hans F A Vasen Journal: Gastroenterology Date: 2006-03 Impact factor: 22.682
Authors: Marjolijn J L Ligtenberg; Roland P Kuiper; Tsun Leung Chan; Monique Goossens; Konnie M Hebeda; Marsha Voorendt; Tracy Y H Lee; Danielle Bodmer; Eveline Hoenselaar; Sandra J B Hendriks-Cornelissen; Wai Yin Tsui; Chi Kwan Kong; Han G Brunner; Ad Geurts van Kessel; Siu Tsan Yuen; J Han J M van Krieken; Suet Yi Leung; Nicoline Hoogerbrugge Journal: Nat Genet Date: 2008-12-21 Impact factor: 38.330
Authors: Renée C Niessen; Jan H Kleibeuker; Helga Westers; Paul O J Jager; Dennie Rozeveld; Krista K Bos; Wytske Boersma-van Ek; Harry Hollema; Rolf H Sijmons; Robert M W Hofstra Journal: Genes Chromosomes Cancer Date: 2009-04 Impact factor: 5.006
Authors: K Robin Yabroff; Cathy J Bradley; Angela B Mariotto; Martin L Brown; Eric J Feuer Journal: J Natl Cancer Inst Date: 2008-12-09 Impact factor: 13.506
Authors: Rebecca A Barnetson; Albert Tenesa; Susan M Farrington; Iain D Nicholl; Roseanne Cetnarskyj; Mary E Porteous; Harry Campbell; Malcolm G Dunlop Journal: N Engl J Med Date: 2006-06-29 Impact factor: 91.245
Authors: Aung Ko Win; John L Hopper; Daniel D Buchanan; Joanne P Young; Albert Tenesa; James G Dowty; Graham G Giles; Jack Goldblatt; Ingrid Winship; Alex Boussioutas; Graeme P Young; Susan Parry; John A Baron; David Duggan; Steven Gallinger; Polly A Newcomb; Robert W Haile; Loïc Le Marchand; Noralane M Lindor; Mark A Jenkins Journal: Eur J Cancer Date: 2013-02-22 Impact factor: 9.162
Authors: Elena M Stoffel; Erika Koeppe; Jessica Everett; Peter Ulintz; Mark Kiel; Jenae Osborne; Linford Williams; Kristen Hanson; Stephen B Gruber; Laura S Rozek Journal: Gastroenterology Date: 2017-11-14 Impact factor: 22.682
Authors: Amelie Echle; Heike Irmgard Grabsch; Philip Quirke; Piet A van den Brandt; Nicholas P West; Gordon G A Hutchins; Lara R Heij; Xiuxiang Tan; Susan D Richman; Jeremias Krause; Elizabeth Alwers; Josien Jenniskens; Kelly Offermans; Richard Gray; Hermann Brenner; Jenny Chang-Claude; Christian Trautwein; Alexander T Pearson; Peter Boor; Tom Luedde; Nadine Therese Gaisa; Michael Hoffmeister; Jakob Nikolas Kather Journal: Gastroenterology Date: 2020-06-17 Impact factor: 22.682
Authors: Darlene Veruttipong; Amr S Soliman; Samuel F Gilbert; Taylor S Blachley; Ahmed Hablas; Mohamed Ramadan; Laura S Rozek; Ibrahim A Seifeldin Journal: World J Gastroenterol Date: 2012-08-14 Impact factor: 5.742